Novo Nordisk A/S ADR (NVO) News

Novo Nordisk A/S ADR (NVO): $126.90

0.77 (+0.61%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter NVO News Items

NVO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NVO News Highlights

  • NVO's 30 day story count now stands at 21.
  • Over the past 27 days, the trend for NVO's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
  • API, DRUG and ADD are the most mentioned tickers in articles about NVO.

Latest NVO News From Around the Web

Below are the latest news stories about NOVO NORDISK A S that investors may wish to consider to help them evaluate NVO as an investment opportunity.

Novo Nordisk Earns 92 RS Rating, Showing Market Leadership

Novo Nordisk ADR had its Relative Strength (RS) Rating upgraded from 89 to 92 Tuesday. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. This proprietary rating identifies market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the last 52 weeks matches up against the rest of the market.

Yahoo | November 29, 2022

11 Best Diabetes Stocks To Buy Now

In this article, we discuss 11 best diabetes stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Diabetes Stocks To Buy Now. The global diabetes market is segmented based on the type, drug class, and devices used to treat the condition. Based on the type, the […]

Yahoo | November 27, 2022

Should You Invest in Novo Nordisk A/S (NVO) Stock?

ClearBridge Investments, an investment management company, published its “ClearBridge International Growth ADR Strategy” third quarter 2022 investor letter. A copy of the same can be downloaded here. The strategy outperformed its benchmark in the third quarter, the MSCI EAFE Index. Overall stock selection and sector allocation attributed to the strategy’s performance in the quarter. In addition, […]

Yahoo | November 24, 2022

3 Healthcare Stocks That Could Set You Up For Life

Until that day, companies in the healthcare sector that can stay ahead of the curve will continue to thrive. Although this market is competitive, the company made its name by targeting the life sciences industry. In other words, Veeva Systems is a specialist, not a generalist.

Yahoo | November 24, 2022

15 Biggest European Pharmaceutical Companies

In this piece, we will take a look at the 15 biggest European pharmaceutical companies. For more companies, head on over to 5 Biggest European Pharmaceutical Companies. Alongside the United States, Europe has some of the most advanced industries and economies in the world. While the Americans are rightly credited with having pioneered the modern […]

Yahoo | November 23, 2022

Prothena (PRTA) Earns Milestone Payment From Novo Nordisk

Prothena (PRTA) earns a $40 million milestone payment from Novo Nordisk following the progress of NNC6019 in a phase II study for the treatment of ATTR cardiomyopathy.

Yahoo | November 22, 2022

Novo Nordisk To Invest Over DKK5B To Add API Production Capacity To Danish Plant

Novo Nordisk A/S (NYSE: NVO) plans to invest DKK 5.4 billion to expand its existing facilities in Bagsvaerd, Denmark. The plans also include constructing a new plant to extend the existing facilities. Novo, the world's biggest producer of diabetes drugs, said the project is expected to be finalized in 2024 and create about 160 new jobs. The investment would establish additional capacity in research and development for manufacturing of active pharmaceutical ingredients (API), the main biologicall

Yahoo | November 22, 2022

UPDATE 2-Drug maker Novo Nordisk invests $744 mln to expand Danish plant

Danish drug maker Novo Nordisk said on Tuesday it plans to invest 5.4 billion Danish crowns ($744 million) to expand its facilities in Bagsvaerd, Denmark. The world's biggest producer of diabetes drugs, Novo said the project is expected to be finalised in 2024 and create about 160 new jobs. The investment would add capacity in research and development for manufacturing of active pharmaceutical ingredients (API), the main biologically active components of medicines, to supply its global clinical trials.

Yahoo | November 22, 2022

Drug maker Novo Nordisk invests $744 million to expand Danish plant

COPENHAGEN (Reuters) -Danish drug maker Novo Nordisk said on Tuesday it plans to invest 5.4 billion Danish crowns ($744 million) to expand its facilities in Bagsvaerd, Denmark. The world's biggest producer of diabetes drugs, Novo said the project is expected to be finalised in 2024 and create about 160 new jobs. The investment would add capacity in research and development for manufacturing of active pharmaceutical ingredients (API), the main biologically active components of medicines, to supply its global clinical trials.

Yahoo | November 22, 2022

Novo Nordisk invests DKK 5.4 bn Danish kroner in expansion of clinical manufacturing facilities in Bagsværd, Denmark

Bagsværd, Denmark, 22 November 2022 – Novo Nordisk today announced plans to invest 5.4 bn Danish kroner in the expansion of existing facilities in Bagsværd. The plans also include the construction of a new plant located in extension of the existing facilities. The investment will establish additional capacity in R&D for manufacturing of active pharmaceutical ingredients (API) to supply our global clinical trials. These expansions will provide capacity for developing Novo Nordisk’s future oral an

Yahoo | November 22, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7355 seconds.